<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03867370</url>
  </required_header>
  <id_info>
    <org_study_id>JS001-020-Ib-HCC</org_study_id>
    <nct_id>NCT03867370</nct_id>
  </id_info>
  <brief_title>Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma</brief_title>
  <official_title>A Phase Ib/II, Open-Label, Multi-Center Study Evaluating the Efficacy and Safety of Neoadjuvant Toripalimab Injection (JS001) or Toripalimab in Combination With Lenvatinib for Patients With Resectable Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate efficacy and safety of Toripalimab Injection (JS001) with or without&#xD;
      Lenvatinib as a Neoadjuvant Therapy in patients with Resectable Hepatocellular Carcinoma&#xD;
      (HCC)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2019</start_date>
  <completion_date type="Anticipated">October 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 27, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>CPRï¼ŒMPR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to 2 months</time_frame>
    <description>ORR is defined as the percentage of participants who achieved CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of R0 resection</measure>
    <time_frame>up to 8 months</time_frame>
    <description>Used for assessment of the feasibility of the neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to operation</measure>
    <time_frame>up to 8 months</time_frame>
    <description>Used for assessment of the feasibility of the neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Used for assessment of the efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Used for assessment of the efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Safety will be recorded through the incidence of adverse events, serious adverse events and specific laboratory abnormalities (worst grade) in each treatment arm.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Toripalimab, Lenvatinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W and lenvatinib for up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (Toripalimab, Lenvatinib)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab (JS001 )</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab (JS001 ) Lenvatinib</intervention_name>
    <description>Given IV 4 mg capsules</description>
    <arm_group_label>Group B (Toripalimab, Lenvatinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab (JS001 ) Lenvatinib</intervention_name>
    <description>Given IV 4 mg capsules</description>
    <arm_group_label>Group C (Toripalimab, Lenvatinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Confirmed by histopathological or cytological examination; The criteria for resectability&#xD;
        is met; Has at least one evaluable lesion according to the RECIST 1.1 standard and has not&#xD;
        received local treatment;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who previously received anti-programmed death receptor-1 (PD-1) antibody,&#xD;
        anti-programmed death ligand-1 (PD-L1) antibody, anti-programmed death ligand-2 (PD-L2)&#xD;
        antibody or anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibodies, including&#xD;
        those who have participated in a JS001 clinical study;&#xD;
&#xD;
        Patients with a history of gastroesophageal varices or active cardia ulcers associated with&#xD;
        a high risk of bleeding; Patients who have upper gastrointestinal hemorrhage within 1 year;&#xD;
        Patients known to have fibrous layer HCC, sarcomatoid HCC or mixed cholangiocarcinoma and&#xD;
        HCC; Other protocol defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jia Fan</last_name>
    <phone>+86-021-64041990</phone>
    <email>fan.jia@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Fan</last_name>
      <phone>021-64041990</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

